AriBio receives first tranche of Fosun Pharma payment in Alzheimer's licensing deal

Swift transfer eases investor concerns over payment risk in cross-border biotech transactions

South Korean biotechnology company AriBio said it has received an initial $10mn payment from China's Fosun Pharma (02196.HK) under a global exclusive licensing agreement for its Alzheimer's drug candidate AR1001, with the funds transferred just ten days after the deal was announced.

The payment represents the first instalment of a $60mn upfront fee included in the agreement. The speed of the transfer has been noted by industry observers as a sign of confidence in the drug's commercial prospects, and as a partial remedy to a persistent concern in biotech licensing: that announced deals are not always followed by prompt payment.

Cross-border fund transfers from China are typically subject to lengthy approval procedures through the State Administration of Foreign Exchange, with large overseas royalty payments often taking several months to clear. Fosun Pharma's prompt remittance is being interpreted as a signal of its commitment to the agreement and its belief in AR1001's clinical and commercial potential. The company is said to be advancing domestic regulatory procedures in China to complete payment of the remaining $50mn upfront fee by June.

AR1001 is currently being evaluated in a global phase 3 trial known as POLARIS-AD, spanning 13 countries with approximately 1,500 participants enrolled. AriBio said around 95% of patients have joined an extension study, a participation rate the company describes as evidence of both the drug's safety profile and patient confidence in long-term treatment.

The drug is being closely watched as a potential first-in-class oral therapy for Alzheimer's disease, a distinction that would set it apart from recently approved treatments such as Eisai and Biogen's lecanemab, which are administered intravenously.

AriBio is separately pursuing a merger with Solux, through which it plans to develop a convergence platform spanning artificial intelligence, data centers and biotechnology.